PFE, GTLB, COP Hit 52-Week Highs on Vaccine Optimism, Strong Earnings, and Rising Oil

Pfizer (PFE) rose 1.65% to a 52-week high of $29.09 after FDA approval of its updated COVID-19 vaccine, positive Phase 3 Lyme disease vaccine data, and a raised full-year revenue outlook. GitLab (GTLB) surged nearly 10% to $55.55 on strong fiscal Q2 results with 21% revenue growth and 42% net ARR growth, prompting Wall Street price target hikes.

Why it matters: ConocoPhillips (COP) gained 0.74% as rising oil prices from the Strait of Hormuz conflict lifted energy stocks.